IDYA
Price
$33.13
Change
-$0.58 (-1.72%)
Updated
Nov 19 closing price
Capitalization
2.9B
131 days until earnings call
Intraday BUY SELL Signals
STRO
Price
$0.91
Change
+$0.02 (+2.25%)
Updated
Nov 19 closing price
Capitalization
76.07M
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs STRO

Header iconIDYA vs STRO Comparison
Open Charts IDYA vs STROBanner chart's image
IDEAYA Biosciences
Price$33.13
Change-$0.58 (-1.72%)
Volume$925.24K
Capitalization2.9B
Sutro Biopharma
Price$0.91
Change+$0.02 (+2.25%)
Volume$588.83K
Capitalization76.07M
IDYA vs STRO Comparison Chart in %
IDYA
Daily Signal:
Gain/Loss:
STRO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IDYA vs. STRO commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and STRO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (IDYA: $33.13 vs. STRO: $0.89)
Brand notoriety: IDYA and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 78% vs. STRO: 57%
Market capitalization -- IDYA: $2.9B vs. STRO: $76.07M
IDYA [@Biotechnology] is valued at $2.9B. STRO’s [@Biotechnology] market capitalization is $76.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than STRO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while STRO’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • STRO’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than STRO.

Price Growth

IDYA (@Biotechnology) experienced а +3.69% price change this week, while STRO (@Biotechnology) price change was +10.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

STRO is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.9B) has a higher market cap than STRO($76.1M). IDYA YTD gains are higher at: 28.911 vs. STRO (-51.440). STRO has higher annual earnings (EBITDA): -164.93M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. STRO (205M). STRO has less debt than IDYA: STRO (19.6M) vs IDYA (26.6M). STRO has higher revenues than IDYA: STRO (104M) vs IDYA (7M).
IDYASTROIDYA / STRO
Capitalization2.9B76.1M3,816%
EBITDA-380.2M-164.93M231%
Gain YTD28.911-51.440-56%
P/E RatioN/AN/A-
Revenue7M104M7%
Total Cash670M205M327%
Total Debt26.6M19.6M136%
FUNDAMENTALS RATINGS
IDYA vs STRO: Fundamental Ratings
IDYA
STRO
OUTLOOK RATING
1..100
1364
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
18
Undervalued
PROFIT vs RISK RATING
1..100
59100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
3864
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STRO's Valuation (18) in the Pharmaceuticals Major industry is in the same range as IDYA (26) in the null industry. This means that STRO’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (59) in the null industry is somewhat better than the same rating for STRO (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew somewhat faster than STRO’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to STRO’s over the last 12 months.

IDYA's Price Growth Rating (38) in the null industry is in the same range as STRO (64) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to STRO’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to STRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYASTRO
RSI
ODDS (%)
Bearish Trend 1 day ago
56%
Bearish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
66%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
76%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
STRO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FOBPX20.970.06
+0.29%
Tributary Balanced Instl Plus
MITEX16.70N/A
N/A
Matthews Asia Innovators Institutional
GAHPX29.66N/A
N/A
Goldman Sachs Emerging Markets Eq P
OANMX159.95-0.36
-0.22%
Oakmark Institutional
OAIEX14.80-0.10
-0.67%
Optimum International A

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-1.72%
NUVL - IDYA
59%
Loosely correlated
+2.71%
NRIX - IDYA
58%
Loosely correlated
+13.09%
XENE - IDYA
58%
Loosely correlated
+0.15%
OCUL - IDYA
57%
Loosely correlated
+2.81%
IMNM - IDYA
57%
Loosely correlated
-1.06%
More

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with TIL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then TIL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
+0.39%
TIL - STRO
38%
Loosely correlated
-6.15%
IDYA - STRO
37%
Loosely correlated
-1.72%
RGNX - STRO
36%
Loosely correlated
-2.84%
MGNX - STRO
36%
Loosely correlated
-7.79%
AXON - STRO
35%
Loosely correlated
-0.50%
More